NCT05699239

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 326 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis

Conditions

• Hyperphosphatemia Patients on Hemodialysis

Interventions

Type	Name	Description
DRUG	TS-172 10mg bid	oral administration of TS-172 10 mg bid
DRUG	TS-172 30mg bid	oral administration of TS-172 30 mg bid
DRUG	TS-172 60mg bid	oral administration of TS-172 60 mg bid
DRUG	TS-172 20mg tid	oral administration of TS-172 20 mg tid
DRUG	Placebo	oral administration of placebo

Timeline

• Start date: 2023-02-08
• Primary completion: 2023-12-26
• Completion: 2023-12-26
• First posted: 2023-01-26
• Last updated: 2025-02-28

Locations

1 site across 1 country: Japan